Save time and get answers to complex questions with AI chat
Generic brand for latisse?Novartis patent term dabrafenib?Can grapefruit consumption affect lipitor's efficacy?Can wine consumption affect lipitor's cholesterol lowering ability?In what ways has the generic option influenced ruxolitinib's market share?
See the DrugPatentWatch profile for dasatinib
US 6,596,746 B1 is Bristol-Myers Squibb’s patent related to dasatinib. It covers the small-molecule dasatinib and related kinase inhibitors (notably BCR-ABL and Src family kinases), including pharmaceutical compositions and therapeutic use in cancer treatment. This patent is part of a broader dasatinib patent family that includes other jurisdictions (EU, JP, etc.). If you need exact claim language, the full prosecution history, or the current legal status (whether it’s expired or still in force, and term adjustments), you can look it up in public patent databases such as: - Google Patents (entry for US 6,596,746) - USPTO Patents Full-Text and Image Database (PatFT) - Espacenet (Global Patent Index) If you want, I can guide you step-by-step to check the current status or summarize the main claims once you provide access to the specific document details or allow me to look up the latest records.
Other Questions About Dasatinib :